Jefferies Positive on Onyx Pharmaceuticals (ONXX) after NCCN Compendia Listing For Frontline Kyprolis

Article Stock Quotes (1) Comments (0)

Jefferies reiterated its Buy rating and $96 price target on Onyx Pharmaceuticals (NASDAQ: ONXX) after the NCCN has included Kyprolis in its Compendia listing and multiple myeloma guidelines for off-label use in the frontline setting.

The firm called this a surprise move ahead of expectations. They believe it could drive upside.

"We believe this inclusion reflects the positive sentiment key opinion leaders and NCCN have towards Kyprolis, potentially benefiting visibility and adoption at the community levels," the analyst said. "Our current estimates conservatively assume de minimis frontline use 2015/beyond."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $85.65 yesterday, with a 52 week range of $36.48-$93.18.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Brean Capital Raises Onyx (ONXX) Price Target to $115
• Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
• Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?